Grifols Therapeutics LLC
grifols.comTotal trials
47
Active
5
Phase 3
18
Total enrollment
4,465
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Alpha-1 MP | — | — | — | — | 5 | ||
| Xembify | — | — | — | — | — | 2 | |
| Gamunex-C | — | — | — | 4 | |||
| Alpha-1 15% | — | — | — | — | 2 |
Next readouts
- 2026-05
- 2026-08
- 2026-09-29
- 2027-12-31
- 2028-09
Top conditions
- Primary Immunodeficiency6
- Alpha1-Antitrypsin Deficiency3
- COVID-193
- Alpha 1-Antitrypsin Deficiency3
- Immunologic Deficiency Syndrome2
- Cystic Fibrosis2
- Agammaglobulinemia1
- Severe Combined Immunodeficiency1
Frequently asked questions about Grifols Therapeutics LLC
- How many clinical trials does Grifols Therapeutics LLC have on ClinicalTrials.gov?
- Grifols Therapeutics LLC is listed as the lead sponsor on 47 clinical trials in ClinicalTrials.gov, 5 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Grifols Therapeutics LLC's trials are in Phase 3?
- 18 of Grifols Therapeutics LLC's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does Grifols Therapeutics LLC focus on?
- Grifols Therapeutics LLC's most-studied conditions on ClinicalTrials.gov are Primary Immunodeficiency, Alpha1-Antitrypsin Deficiency, COVID-19, Alpha 1-Antitrypsin Deficiency, Immunologic Deficiency Syndrome.
- When are Grifols Therapeutics LLC's next clinical trial readouts?
- Grifols Therapeutics LLC has 5 upcoming primary-completion readouts tracked here; the soonest is “A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma”, expected around 2026-05.